GlassScriptPhysician profile
Susan V Mitchell
NPI 1013452499
$2,848.41
in general payments reported to CMS, 2019-2025
30 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,030 · 2023: $472 · 2024: $701 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $410.25 | 2023-2025 | Belbuca |
| Abbvie INC. | $262.25 | 2022-2025 | |
| Boston Scientific Corporation | $258.45 | 2024-2025 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.00 | 2023-2025 | Relistor |
| Nevro Corp. | $206.95 | 2024 | Senza |
| Averitas Pharma INC. | $182.58 | 2023-2025 | Qutenza |
| Glaxosmithkline, LLC. | $152.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $138.87 | 2022 | |
| Globus Medical, INC. | $126.01 | 2025 | Senza |
| Urovant Sciences INC | $121.08 | 2022 | |
| Novo Nordisk INC | $105.63 | 2022 | |
| Medtronic, INC. | $104.74 | 2023-2025 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $73.33 | 2022 | |
| Nalu Medical, INC. | $65.13 | 2024-2025 | Nalu Neurostimulation System |
| Saluda Medical Americas, INC. | $54.41 | 2023 | Evoke Scs |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $50.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.41 | 2022 | |
| Sumitomo Pharma America, INC. | $44.81 | 2023 | Gemtesa |
| Spr Therapeutics, INC | $35.17 | 2024-2025 | Sprint Pns System |
| Biohaven Pharmaceutical Holding Company LTD. | $28.74 | 2022 | |
| Exact Sciences Corporation | $24.11 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $23.84 | 2022 | |
| Amarin Pharma, INC. | $19.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.10 | 2022 | |
| Horizon Therapeutics Plc | $18.59 | 2022 | |
| Lilly USA, LLC | $17.61 | 2022 | |
| Depuy Synthes Sales INC. | $16.03 | 2024 | Monovisc |
| Therapeuticsmd, INC. | $12.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.77 | 2022 | |
| Grt US Holding, INC. | $10.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.